Beyond lowering LDL, PCSK9 inhibitors may also control thrombo-inflammation, a pleiotropic effect that contributes to risk reduction in patients with uncontrolled hypercholesterolemia and coronary artery disease. Here, PCSK9 is linked to coronary artery disorder.